Pharmaceutical - Pharmaceutical, Durect

Filter

Current filters:

PharmaceuticalDurect

Popular Filters

Pfizer to finally drop Remoxy development

27-10-2014

Shares of Durect Corp plunged 42.9% to $0.79 after it revealed that pharma giant Pfizer has decided to…

DurectLicensingNeurologicalPain TherapeuticsPfizerPharmaceuticalPosidurRemoxyUSA

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

US FDA accepts DURECT's NDA for Posidur

20-06-2013

DURECT Corp (Nasdaq: DRRX) says that the New Drug Application for its investigational product Posidur…

DurectNeurologicalNorth AmericaPharmaceuticalPosidurRegulation

Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners

10-05-2013

US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's…

DurectEli LillyenzastaurinNeurologicalOncologyPain TherapeuticsPfizerPharmaceuticalRegulationRemoxyResearch

Hospira returns Posidur rights to DURECT

02-04-2012

DURECT Corp (Nasdaq: DRRX) says that fellow USA-based that Hospira (NYSE: HSP) has given notice that…

DurectHospiraLicensingNeurologicalNorth AmericaPharmaceuticalPosidur

COMPANY SPOTLIGHT

Menarini

Back to top